Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients

Table 3 Histopathological characteristics of breast cancers in individuals with TP53 germline mutations

Mutation	Patient no.	Age at diagnosis	Diagnosis	Histology	Grade	ER status	PR status	HER-2 status
p. E346X	BRC 901	25	Breast ca, L	IDC with DCIS	NA	-	+	+
		26	Breast ca, L	IDC	3	+	+	3+
		29	Breast ca, R	IDC	NA	NA	NA	NA
p. G334_R335dup	BRC 564	26	Breast ca, R	IDC	NA	NA	NA	NA
		27	Breast ca, L	IDC	3	-	+	3+
p. A138V	BRC 349	33	Breast ca, R	IDC	3	-	-	3+
	BRC 349A	33	Breast ca, L	IDC	2	-	-	-
p. E285K	BRC 832	31	Breast ca, R	IDC	2	-	-	3+
	BRC 873	29	Breast ca, R	IDC with DCIS	3	-	-	3+
		31	Breast ca, L	NA	NA	NA	NA	NA
	BRC 873A	27	Breast ca, L	NA	NA	NA	NA	NA
		31	Breast ca, R	Mucinous	2	+	+	3+

Breast ca, breast cancer; DCIS, ductal carcinoma in situ; ER, estrogen receptor; IDC, invasive ductal carcinoma; HER-2, human epidermal growth factor receptor 2; L, left; NA, not available; PR, progesterone receptor; R, right

ISSN: 1465-542X